Aripiprazole augmentation for major depressive disorder: Dosing patterns in a naturalistic treatment setting

International Clinical Psychopharmacology

Volumn 29, Issue 2, 2014, Pages 116-119

  Pae, Chi Un ^a,c   Wang, Sheng Min ^a   Han, Changsu ^b   Lee, Soo Jung ^a   Patkar, Ashwin A ^b   Masand, Prakash S ^d  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Global Medical Education Inc   (United States)

Author keywords

Aripiprazole; Atypical Antipsychotics; Augmentation; Doses; Major Depressive Disorder

Indexed keywords

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; TREATMENT OUTCOME;

EID: 84895076310     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000012     Document Type: Article

References (28)

1. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. (2007). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-b lind, placebocontrolled study. J Clin Psychiatry 68:843-853.
2. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. (2009). Aripiprazole augmentation in major depressive diso rder: A doubleblind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14:197-206.
3. Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, et al. (2011). Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat 7:303-312.
4. Chen SJ, Hsiao YL, Shen TW, Chen ST (2012). The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: A prospective, open-label trial. J Clin Psychopharmacol 32:56-60.
5. Chon g SA, Tan CH, Khoo YM, Lee HS,Wong KE, Ngui F, et al. (1997). Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit 19:219-223.
6. Diaz FJ, De Leon J (2002). Excessive antipsychotic dosing in 2 U.S. State hospitals. J Clin Psychiatry 63:998-1003.
7. Dording C, Cassiello C, F King, Pencina M, Fava M, Mischoulon D (2013). The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. Int Clin Psychopharmacol 28:238-244.
8. Fava M, Mischoulon D, Iosifescu D, Wi tte J, Pencina M, Flynn M, et al. (2012). A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 81:87-97.
9. Han C, Pae CU (2013). Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder CNS Drugs 27 (Suppl 1):S47-S51.
10. Hartung DM, Wisdom JP, Pollack DA, Hamer AM, Haxby DG, Middleton L, et al. (2008). Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J Clin Psychiatr y 69:1540-1547.
11. Horstmann S, Binder EB (2009). Pharmacogenomics of antidepressant drugs. Pharmacol Ther 124:57-73.
12. Jing Y, Guo Z, Kalsekar I, Forbes RA, Hebden T, T hase ME (2013). Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010). Int Clin Psychopharmacol 28:87-90.
13. Jon DI, Kim D, Seo HJ, Kwon YJ, Kim MD , Yang JC, et al. (2013). Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: A 6-week prospective open-label multicenter study. Clin Neuropharmacol 36:157-161.
14. Lin CH, Lin SH, Jang FL (2011). Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: A randomized, double-blind, controlled study. J Clin Psychopharmacol 31:563-568.
15. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. (2008). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-b lind, placebo-controlled study. J Clin Psychopharmacol 28:156-165.
16. Mischoulon D,Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, et al. (2012). Efficacy of dose increase among nonresponders to low- dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: A randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry 73:353-357.
17. Nelson JC, Pikalov A, Be rman RM (2008). Augmentation treatment in major depressive disorder: Focus on aripiprazole. Neuropsychiatr Dis Treat 4: 937-948.
18. Nelson JC, Papakostas GI (2009). Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980-991.
19. Nierenberg AA, Trivedi MH, Gaynes BN, Mitchell J, Davis LL, Husain MM, et al. (200 9). Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder. Aust N Z J Psychiatry 43:956-967.
20. Pae CU, Patkar AA, Jun TY, Lee C, Masand PS, Paik IH (2007). Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety 24:522-526.
21. Pae CU, Sohi MS, Seo HJ, Serretti A, Patkar AA, Steffe ns DC, et al. (2010). Quetiapine XR: Current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 34:1165-1173.
22. Pae CU, Forbes A, Patkar AA (2011). Aripipr azole as adjunctive therapy for patients with major depressive disorder: Overview and implications of clinical trial data. CNS drugs 25:109-127.
23. Pae CU, Bodkin JA, Portland KB, Thase ME, Patkar AA (2012). Sa fety of selegiline transdermal system in clinical practice: Analysis of adverse events from postmarketing exposures. J Clin Psychiatry 73:661-668.
24. Pae CU, Jeon H, Lee B, Seo HJ, Kim S, Park EJ, et al . Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: A 12-week prospective open-label multicenter study. Int Clin Psychopharmacol (in press).
25. Patkar AA, Peindl K, Mago R, Mannelli P, Masand PS (2006). An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 8:82-87.
26. Shen H, He MM, Liu H,Wrighton SA,Wang L, Guo B, et al. (2007). Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 35:1292-1300.
27. Steffens DC, Nelson JC , Eudicone JM, Andersson C, Yang H, Tran QV, et al. (2011). Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: A pooled subpopulation analysis. Int J Geriatr Psychiatry 26:564-572.
28. Yoon JS (1995). Measuring ethnic differences in response to psychotropic drugs. In: Hindmarch I, Stonier PD, editors. Human psychopharmacology: Measures and methods. Chichester: John Wiley & Sons Ltd.